ASB2 and acute myeloid leukemia: Li et al. reported that FTO promoted the progression of AML by facilitating the transformation of leukemic oncogene-mediated cell and leukemogenesis and repressing the response of APL cells to ATRA treatment through down-regulating ASB2 and RARA expression in an m6A-dependent pathway [22].